



Microwave-assisted expeditious and efficient synthesis of novel quinolin-4-yl methoxychromen-2-and-4-ones catalyzed by YbCl₃ under solvent free one-pot three components domino reaction and their antimicrobial activity

Journal:	<i>RSC Advances</i>
Manuscript ID	RA-ART-08-2015-015748.R1
Article Type:	Paper
Date Submitted by the Author:	10-Oct-2015
Complete List of Authors:	Ahmed, Naseem; Naseem Ahmed, ; Indian Institute of Technology Roorkee, Kumar, Sumit; Indian Institute of Technology Roorkee, Chemistry Patel, Alok; 1, Department of Biotechnology
Subject area & keyword:	Bioorganic chemistry < Chemical biology & medicinal

Graphical Abstract

Microwave-assisted expeditious and efficient synthesis of novel quinolin-4-yl methoxychromen-2- and -4-ones catalyzed by YbCl₃ under solvent free one-pot three components domino reaction and their antimicrobial activity

Sumit Kumar,^a Alok Patel^b and Naseem Ahmed^{a,*}


^aDepartment of Chemistry, Indian Institute of Technology Roorkee, Roorkee 247 667, Uttarakhand, India.

^bDepartment of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247 667, Uttarakhand, India.

*Corresponding author. Fax and Tel.: +91 1332 285745.

E-mail address: nasemfcy@iitr.ac.in

Table of contents



- A novel catalytic method for MW assisted multicomponent A³ synthesis was developed.
- Novel Quinolin-4-yl methoxy-chromen-2 and-4-ones were synthesized.
- High yields, shorter reaction time, neat condition, reuse of YbCl₃ are main features.
- This method is green and milder but more advanced than those earlier reported.



Journal Name

ARTICLE

Microwave-assisted expeditious and efficient synthesis of novel quinolin-4-yl methoxychromen-2- and -4-ones catalyzed by YbCl_3 under solvent free one-pot three components domino reaction and their antimicrobial activity

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

Sumit Kumar,^a Alok Patel^b and Naseem Ahmed^{1a,*}

www.rsc.org/

An efficient and highly eco-friendly synthesis of diverse and functionalized quinolin-4-yl methoxychromen-2- and -4-ones via one-pot three-components domino reaction of propargylated-flavone or -coumarin with aldehydes and anilines under solvent-free and microwave condition is described using YbCl_3 as catalyst. The reaction took 4 min to give the desired products in excellent yields (80–95%) at 100 °C. This approach has advantages such as high yields, solvent-free mild reaction conditions, functional group tolerance, 95% atom-economy and recyclability of catalyst. Synthesized compounds were examined for their antimicrobial activity. Among the tested compounds, compounds **4n**, **5f**, **5g** and **5h** showed the excellent antimicrobial activity.

1. Introduction

Quinoline-containing molecules are present in a number of natural products and have shown different uses such as luminescent materials,¹ tunable ligands² and drug agents like antimalarial, antibacterial, anticancer, antihypertensive, antitubercular and anti-inflammatory^{3–7} (Fig. 1).




Fig. 1 Some clinically used drugs bearing a Quinoline moiety.

Therefore, various methods have been reported over the past 130 years for their synthesis that includes Skraup,⁸ Doebner-Von Miller,⁹ Pfitzinger,¹⁰ Conrad-Limpach,¹¹ Combes¹² and Friedländer syntheses.¹³ Recently, different catalysts such as CuCl ,¹⁴ CuBr ,¹⁵ $\text{Cu}(\text{OTf})_2$,¹⁶ InCl_3 ,¹⁷ FeCl_3 ,¹⁸ $\text{Fe}(\text{OTf})_3$,¹⁹ AgOTf ,²⁰ $\text{AuCl}_3/\text{CuBr}$,²¹ NbCl_5 ,²² $\text{Yb}(\text{pfb})_3$,²³ $\text{Cu}/\text{La}(\text{OTf})_3$,²⁴ montmorillonite K-10²⁵ for A^3 -coupling reaction of alkyne, aldehyde and amine have been explored. Mostly, these procedures are marred by one or other drawbacks such as conventional Lewis and Brønsted acids, long reaction time, harsher reaction conditions, low atom economy, and use of refractory substrates. Therefore, the development of expeditious, efficient and eco-friendly approaches for their preparation is of crucial importance.

In recent years, the chemistry of rare earth metals has been under broad examinations due to their extensive applications in organic chemistry.^{26,27} Especially, the salts of inner-transition metals like chlorides and triflates have been used as Lewis acid catalysts due to low water sensitivity, reusability and stoichiometric use compared to commonly used water sensitive Lewis acid catalysts like BF_3 , AlCl_3 , TiCl_4 , etc.²⁸ Recently, microwave-assisted synthesis has been recognized for its capability to enhance chemical transformations and produce clean and high-yielding chemical reactions without further purification.²⁹ Similarly, multicomponent/tandem reactions (MCRs) are a powerful method for the synthesis of heterocyclic compounds and are found to be more efficient compared to conventional stepwise synthesis because of excellent atom economy, reduction of wastes, reaction time, cost and labour.³⁰

In continuous pursuit of our interest for both the academic and the industrial researchers,³¹ it is desirable to explore the scope of rare earth metals as Lewis acids under microwave-assisted organic synthesis due to their unique and substantial advantages. Recently, we found YbCl_3 an efficient catalyst in the synthesis of biologically active heterocycles.^{31a} Therefore, keeping in mind the extraordinary pharmacological potential of various heterocyclic moieties such as quinoline, flavone and coumarin, herein we devise an efficient and eco-friendly green approach for the synthesis of bioactive novel Quinolin-4-yl methoxychromen-2- and -4-ones via employing one-pot three-component domino reaction of aldehydes, amines and propargylated-flavone or -coumarin using YbCl_3 (2 mol%) under solvent free microwave condition (Scheme 1).

2. Results and discussion

2.1. Chemistry

The starting materials 2-(4-chlorophenyl)-3-(prop-2-yn-1-yloxy)-4H-chromen-4-one (**1a**) and 4-methyl-7-(prop-2-yn-1-yloxy)-2H-chromen-2-one (**1b**) were synthesized by following the literature procedure.^{31b}


^aDepartment of Chemistry, Indian Institute of Technology Roorkee, Roorkee 247 667, Uttarakhand, India.

^bDepartment of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247 667, Uttarakhand, India.

*Corresponding author. Fax and Tel.: +91 1332 285745.

E-mail address: naseemfcy@iitr.ac.in


Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x



Scheme 1. Microwave-assisted A³ synthesis of quinolin-4-yl methoxy-chromen-2 and -4-ones.

As shown in Table 1, in a prototypical reaction, 2-(4-chlorophenyl)-3-(prop-2-yn-1-yloxy)-4H-chromen-4-one **1a**, was treated with aniline **2a** and benzaldehyde **3a** at 100 °C (oil bath) for 60 min which afforded the product **4a** in 81% yield (Table 1, entry 1). In spite of appreciable results, to find optimum protocol for the transformation, several other conditions for the reaction were explored.

Table 1. Optimization of reaction conditions for the formation of compound **4a**.^a



Entry	Solvent	Catalyst (mol%)	Condition	Temp. (°C)	Time (min)	Yield ^d (%)
1	neat	2	CH ^c	100	60	81
2	neat	2	MW ^b	100	10	95
3	neat	2	MW ^b	100	7	95
4	neat	2	MW ^b	100	4	95
5	neat	2	MW ^b	100	3	77
6	neat	2	MW ^b	120	4	89
7	neat	2	MW ^b	80	8	62
8	neat	3	MW ^b	100	4	95
9	neat	1	MW ^b	100	7	79
10	neat	2	grinding	rt	50	5
11	ACN	2	MW ^b	80	10	65
12	THF	2	MW ^b	65	10	59
13	CHCl ₃	2	MW ^b	60	10	71


^aGeneral condition: 2-(4-chlorophenyl)-3-(prop-2-yn-1-yloxy)-4H-chromen-4-one **1a** (1.5 mmol), aniline **2a** (1 mmol), benzaldehyde **3a** (1 mmol); ^bAnton Paar Monowave 300 reactor. Irradiation Power: 850 W; Ramp time: 1 min. 70 °C; holding temp: 100 °C; ^cConventional heating; ^dIsolated yield.

The efficiency of the reaction was studied in different heating regime for example in microwave condition and to our delight; reaction proceeded smoothly increasing the yield of **4a** to 95% in just 10 min (Table 1, entry 2). To observe the effect of

















microwave condition, the reaction was irradiated for variable times (Table 1, entries 3-5) and temperature (Table 1, entries 6-7). It was observed that lowering down the irradiation time to 7 and 4 min remained equally effective (Table 1, entries 3, 4), but further reducing it to 3 min decreased the yield of **4a** to 77% (Table 1, entry 5). Similarly, increasing and decreasing the temperature of the reaction system did not bring the desired results (Table 1, entries 6, 7). Then, the effect and the amount of the YbCl₃ on the efficiency and yield of the product were briefly examined. It was notable that YbCl₃ played a vital role in the reaction system; in its absence reaction did not proceed under the same reaction conditions. However, increasing the catalyst loading of YbCl₃ to 3 mol% did not improve the product yield whereas decreasing the loading to 1 mol% lowered the yield significantly to 79% (Table 1, entries 8, 9). On the other hand, neat grinding of substrates and the catalyst for 50 min at ambient temperature resulted in scanty yield of the product **4a** (5%, Table 1, entry 10).







After that the effect of the solvent on the reaction system was also investigated. CHCl₃ was found to be a good solvent affording the product **4a** in 71% yield (Table 1, entry 13) while acetonitrile and THF provided the moderate yields (Table 1, entries 11, 12). So, it led to conclude that microwave irradiation at 100 °C for 4 minutes in neat condition was the optimal condition for the reaction to get best yield of the product **4a**. Recently, from the viewpoint of green chemistry, solvent-free condition is highly demanded, so we carried out the reaction in neat condition.

After getting optimization conditions, the substrate scope with respect to aldehyde and aryl amine was also examined (Table 2). Both electron-rich and electron-deficient anilines provided excellent yields. Electron-deficient aldehydes reacted with aniline and propargylated-flavone very efficiently in excellent yields but some electron-rich aromatic aldehydes need harsher condition (120 °C MW). However, it should be mentioned that substituent effect on arylamine might affect the yields. This may be ascribed to the nature of nucleophilicity of amines, which is critical in the formation of imines from benzaldehydes and amines.

Table 2. Scope of reaction for A³ synthesis of quinolin-4-yl methoxy-chromen-4-ones (**4a-q**).

Entry	Propargylated flavone	Aniline	Aldehyde	Product	Temp (°C)	Yield ^a (%)
1	1a				100	95
2	1a				100	94
3	1a				100	91
4	1a				100	89
5	1a				100	86
6	1a	2a			120	84

ARTICLE			Journal Name			
7	1a	2a	 <p>3c</p>	 <p>4g</p>	100	90
8	1a	2a	 <p>3d</p>	 <p>4h</p>	100	88
9	1a	2a	 <p>3e</p>	 <p>4i</p>	120	86
10	1a	2a	 <p>3f</p>	 <p>4j</p>	120	90
11	1a	2d	 <p>3f</p>	 <p>4k</p>	120	89
12	1a	2d	 <p>3e</p>	 <p>4l</p>	120	85
13	1a	2b	 <p>3d</p>	 <p>4m</p>	100	90
14	1a	2b	 <p>3j</p>	 <p>4n</p>	100	85









15	1a	2b			120	86
16	1a	2d			100	92
17	1a	2b			100	87













^aIsolated yield.

Furthermore, the reaction was tested on other terminal alkyne 4-methyl-7-(prop-2-yn-1-yloxy)-2H-chromen-2-one (**1b**) also. After having obtained success with quinolin-4-yl methoxy-chromen-4-ones (**4a-q**), we extended the protocol for the formation of quinolin-4-yl methoxy-chromen-2-ones (**5a-h**) and

delightfully on this scaffold also it worked equally well as shown in Table 3. The reaction tolerated various aryl- or heteroaryl-aldehydes and generally similar reactivity trend was observed in both the series.

Table 3. Scope of reaction for A³ synthesis of quinolin-4-yl methoxy-chromen-2-ones (**5a-h**).

Entry	Propargylated Coumarin	Aniline	Aldehyde	Product	Temp (°C)	Yield ^a (%)
1					100	94
2					120	91

3	1b	2d	 <p>3e</p>	 <p>5c</p>	120	89
4	1b	2d	 <p>3g</p>	 <p>5d</p>	120	85
5	1b	2d	 <p>3d</p>	 <p>5e</p>	100	86
6	1b	2d	 <p>3i</p>	 <p>5f</p>	100	88
7	1b	2d	 <p>3h</p>	 <p>5g</p>	120	85
8	1b	2d	 <p>3j</p>	 <p>5h</p>	100	80

^aIsolated yield.

The assigned structures of new products (**4a-q** and **5a-h**) were established from their spectroscopic data (IR, ¹H, ¹³C NMR and HRMS). For example, IR spectrum of **4f** showed absorptions at 1703 (>C=O), 1695 (>C=C< flavone moiety) and 1630 (>C=N-) cm⁻¹. HR-MS of **4f** supported a molecular composition of

C₃₃H₂₅ClN₂O₃, representing 22 degrees of unsaturation. In the ¹H-NMR spectrum of **4f**, peak at δ_H6.59 ppm (d, *J* = 10 Hz, 2H) appeared for 10'-H, dimethylamino group occurred at δ_H2.96 ppm (s, 6H) and two methylene protons (-CH₂) resonating at δ_H4.94 ppm (s, 2H). In ¹³C-NMR spectrum, δ_C 174.6ppm

confirms the presence of carbonyl group of flavone moiety. The characteristic peaks at δ_c 160.3 (C-4'), 155.2 (C-2), 155.0 (C-9), 154.2 (C-2'), 152.7 (C-13') and 76.5 (C-15) ppm confirm the formation of product **4f**. Likewise, in second series of the compounds (**5a-h**), characteristic peaks of coumarin moiety such as olefinic proton in the range of δ_H 6.15-6.65 ppm and ester carbonyl at δ_c 161.9-164.9 ppm are in full agreement with the formation of the title compounds (Please see ESI).


An important feature of catalyst is the recovery and reusability of the catalyst in the reaction which is shown in the recycling experiments of this catalysis on the reaction of benzaldehyde, aniline and 2-(4-chlorophenyl)-3-(prop-2-yn-1-yloxy)-4H-chromen-4-one (**1a**) (Table 4). After completion, the reaction mixture was dissolved in CHCl_3 , the catalyst was filtered off and washed with CHCl_3 (3x10 mL) and recovered YbCl_3 showed good catalytic activity as the product **4a** obtained in 95, 90, 86 and 79% yield in at least four cycles in subsequent reactions respectively.

Table 4. Catalyst reuses.

Entry	Run	Time (min)	Yield (%) ^a
1	1 st	4	95
2	2 nd	4	90
3	3 rd	4	86
4	4 th	4	79

^aIsolated yield.

On the basis of above results, the proposed mechanism for this one-pot synthesis of quinolin-4-yl methoxy-chromen-4-ones is depicted in Scheme 2.



Scheme 2. The plausible mechanism of one-pot synthesis of quinolin-4-yl methoxy-chromen-4-ones catalyzed by YbCl_3 .

This one-pot three component reaction undergoes domino imine formation, subsequently imine addition and cyclization then finally oxidation. The high reactivity of YbCl_3 is ascribed to the smaller radius of the Yb^{3+} and the H_2O in the reaction system do not deactivate or decompose the catalyst. On the basis of HSAB theory, the hard Lewis base site of nitrogen lone pair is coordinated by hard Lewis acid Yb^{3+} and enhances the electrophilicity of the imine and then cyclization occurs followed by aromatization. Yb^{3+} played an important role in both processes of imine addition and cyclization.

2.2. Biological Activity

The newly synthesized compounds were evaluated for their *in vitro* antibacterial activity against *S. aureus* and *B. subtilis* as examples of Gram-positive bacteria and *E. coli* and *S. flexneri* as examples of Gram-negative bacteria. They were also evaluated for their *in vitro* antifungal potential against *Candida albicans* fungal strain.

Table 5. Minimum inhibitory concentration (MIC, mg/mL^{-1}) of some newly synthesized compounds against bacterial and fungal strains

Compound	Gram-positive		Gram-negative		Fungus
	<i>S. aureus</i>	<i>B. subtilis</i>	<i>E. coli</i>	<i>S. flexneri</i>	<i>C. albicans</i>
4a	>100	>100	>100	50	25
4b	12.5	12.5	50	12.5	12.5
4e	25	>100	25	12.5	12.5
4f	12.5	12.5	0.78	3.12	25
4g	25	25	12.5	50	3.12
4m	25	50	>100	12.5	50
4n	0.39	3.12	1.56	3.12	6.25
4o	25	6.25	12.5	6.25	25
4p	50	25	50	50	>100
4q	1.56	6.25	1.56	12.5	25
5a	>100	12.5	>100	50	3.12
5d	6.25	3.12	3.12	12.5	25
5f	3.12	50	0.39	3.12	25
5g	6.25	3.12	0.39	6.25	0.39
5h	1.56	0.39	0.78	3.12	12.5
Ampicillin	0.78	0.39	1.56	0.78	-
Cefadroxil	1.56	3.12	0.78	1.56	-
Fluconazole	-	-	-	-	3.12

2.2.1. Antibacterial activity. As seen in the Table 5, compound **4n** (MIC: 0.39 mg/ml) and compounds **4q**, **5h** (MIC: 1.56 mg/ml) have shown better or equal antibacterial activity than positive controls against *S. aureus*. In case of *B. subtilis*, all compounds have shown lower activity than Ampicillin while compound **5h** (MIC: 0.39 mg/ml) has shown equal antibacterial activity against *B. subtilis*. Moreover, compounds **4n**, **5d**, **5g** (MIC: 3.12 mg/ml) were found equally potent as Cefadroxil against *B. subtilis*. Compounds **5f** and **5g** (MIC: 0.39 mg/ml) have shown better activity than positive controls against *E. coli* while compounds **4f**, **5h** (MIC: 0.78 mg/ml) and **4n**, **4q** (MIC: 1.56 mg/ml) have shown equal activity to the reference drugs. Compounds **4f**, **4n**, **5f**, **5h** have shown admirable antibacterial activity (MIC: 3.12 mg/ml) against *Shigella flexneri* compared to Ampicillin and Cefadroxil. Thus, the electron releasing group ($\text{N}(\text{CH}_3)_2$) and the compounds carrying heterocyclic moiety like furan, indole or ferrocene (**4n**, **4q** and **5h**) have shown excellent (MIC: 0.39 mg/ml) to good (MIC: 1.56 mg/ml) activity against *S. aureus*. Against *B. subtilis* also, either the electron donating group (OMe) or furan, indole and ferrocene carrying compounds (**4n**, **5d**, **5g**, **5h**) have shown equal (MIC: 0.39 and 3.12 mg/ml) antibacterial activity to the standard drugs. Against *E. coli*, compounds (**4f**, **4n**, **4q**, **5f**, **5g**, and **5h**) have shown excellent activity compared to Ampicillin and Cefadroxil depending on the electron releasing group ($\text{N}(\text{CH}_3)_2$) and heterocyclic moiety (furan, indole or ferrocene) on the quinoline scaffold. Against *Shigella flexneri*, all compounds have shown low activity compared to the standard drugs without depending on functional groups on aromatic ring.

2.2.2. Antifungal activity. Compounds were subjected to MIC (minimum inhibitory concentration) determination by micro-dilution method [31] and the results are given in Table 5. Reference drug Fluconazole was selected as positive control in antifungal activity assay. Compound **5g** had shown excellent antifungal activity (MIC: 0.39 mg/ml) against *C. albicans*. Compounds **4g**, **5a** have shown similar antifungal activity (MIC: 3.12 mg/ml) as Fluconazole against *C. albicans* while others have shown lower activity. Thus, compounds carrying either electron withdrawing group ($-\text{NO}_2$) or indole and ferrocene (**4g**, **4n**, **5a** and **5g**) have shown excellent to moderate antifungal activity (MIC: 1.95 mg/ml) against *C. albicans* compared to standard drug.

3. Conclusion

In summary, we have reported a simple, fast and efficient three-component tandem reaction protocol for the synthesis of novel bioactive quinolin-4-yl methoxy-chromen-2- and -4-ones from aldehydes, amines, and propargylated-flavone or -coumarin using YbCl_3 as catalyst under solvent-free and microwave condition. Products were obtained in excellent yields (80–95%) within 4 min. Mild reaction condition, improved yields, neat condition and reusability of catalyst without any appreciable loss of activity are the main advantages of our protocol. Compounds **4n** and **5h** exhibited the highest biological activity toward Gram-positive bacteria, while compounds **5f** and **5g** showed highest toward Gram-negative bacteria. On the other hand, compound **5g** displayed the highest activity against pathogenic fungi *C. albicans* using the MIC method. Further studies on the synthetic application of YbCl_3 as catalyst in organic transformations are currently underway in our group.

4. Experimental

All the required chemicals were purchased from Merck and Aldrich Chemical Company. Pre-coated aluminium sheets (silica gel 60 F254, Merck) were used for thin-layer chromatography (TLC) and spots were visualized under UV light. IR spectra were recorded with KBr on Thermo Nicolet FT-IR spectrophotometer. ^1H NMR and ^{13}C NMR spectra were recorded respectively on Bruker Spectrospin DPX 500 and Jeol Resonance ECX 400 spectrometer using as solvent and trimethylsilane (TMS) as an internal standard. Spectra were processed using Bruker Topspin® 3.0.b.8. Splitting patterns are designated as follows; s = singlet, d = doublet, dd = doublets of doublet, m = multiplet. Chemical shift (δ) values are given in ppm. High-resolution mass spectra (HRMS) were obtained on a Bruker micrOTOF™-Q II mass spectrometer (ESI/MS).

4.1. Microwave Irradiation Experiment. All microwave experiments were carried out in a dedicated Anton Paar Monowave-300 reactor, operating at a frequency of 2.455 GHz with continuous irradiation power of 0 to 850 W. The reactions were performed in a G-10 Borosilicate glass vial sealed with Teflon septum and placed in amicrowave cavity. Before microwave heating, oxygen was purged into the reaction vial. Initially, microwave of required power was used and temperature was being ramped from room temperature to a desired temperature. Once this temperature was attained, the process vial was held at this temperature for required time. The reactions were continuously stirred. Temperature was measured by an IR sensor. After the experiments a cooling jet cooled the reaction vessel to ambient temperature.

4.2. General procedure for the synthesis of compounds (4a-q and 5a-h): Aldehyde (1 mmol), arylamine (1 mmol), propargylated-flavone or -coumarin (1.2 mmol) and YbCl_3 (6 mg, 2 mol %) were mixed well in a G-10 process vial capped with Teflon septum and oxygen was purged into it. After a pre-stirring for one minute, the vial was subjected to microwave irradiation with the initial ramp time of 1 minute at 70 °C. The temperature was then raised to 100 °C with the holding time of 4 min. The reaction was brought to room temperature, then crude product was dissolved in CHCl_3 (10 mL) and the catalyst was filtered off and washed with CHCl_3 (3×10 mL). The filtrate was washed with water (3×20 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude material was chromatographed on a silica gel column eluting with a mixture of ethyl acetate and hexane. (The purified products were identified by FTIR, NMR and HRMS spectra).

4.3. Characterization data:

4.3.1. 2-(4-chlorophenyl)-3-((2-phenylquinolin-4-yl)methoxy)-4H-chromen-4-one (4a). Yield: 95% as pale yellow liquid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.11 (d, J = 11 Hz, 1H), 7.89-7.87 (m, 3H), 7.71-7.68 (m, 1H), 7.65-7.60 (m, 2H), 7.53 (d, J = 9.5 Hz, 3H), 7.52-7.49 (m, 1H), 7.48-7.46 (m, 1H), 7.44-7.39 (m, 1H), 7.24-7.20 (m, 2H), 6.91-6.87 (m, 3H), 4.98 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 175.4, 158.5, 156.2, 155.3, 140.6, 138.7, 137.2, 136.3, 134.7, 134.1, 133.7, 130.4, 130.2, 129.9, 129.7, 129.3, 129.1, 128.8, 128.5, 125.9, 125.3, 123.8, 120.3, 118.2, 115.5, 86.3, 76.6. FTIR (KBr, ν = cm^{-1}): 3092, 3075, 2953, 2917, 1704, 1695, 1630, 1592, 1513, 1465, 1410, 1325, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{31}\text{H}_{20}\text{ClNNaO}_3$ [$\text{M}+\text{Na}$] $^+$: 512.1023, found: 512.1021.

4.3.2. 2-(4-chlorophenyl)-3-((6-(dimethylamino)-2-phenylquinolin-4-yl)methoxy)-4H-chromen-4-one (4b). Yield: 94% as brownish semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.16 (dd, J = 2, 10 Hz, 1H), 8.06 (d, J = 11 Hz, 2H), 7.93 (dd, J = 1.5, 10 Hz, 2H), 7.73 (dd, J = 2, 10.5 Hz, 2H), 7.64-7.62 (m, 3H), 7.46 (d, J = 10 Hz, 1H), 7.39 (d, J = 11 Hz, 4H), 7.34-7.30 (m, 1H), 7.18 (s, 1H), 4.96 (s, 2H), 2.98 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 174.2, 160.4, 155.1, 155.0, 154.3, 152.5, 143.1, 141.5, 138.4, 136.7, 133.5, 131.5, 130.0, 129.8, 129.7, 129.0, 128.5, 125.5, 125.2, 124.8, 123.7, 118.0, 111.1, 110.8, 110.5, 86.3, 76.5, 42.1. FTIR (KBr, ν = cm^{-1}): 3090, 3072, 2949, 2915, 1705, 1692, 1625, 1594, 1515, 1460, 1412, 1303, 1244, 1176, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{33}\text{H}_{25}\text{ClN}_2\text{NaO}_3$ [$\text{M}+\text{Na}$] $^+$: 555.1445, found: 555.1432.

4.3.3. 2-(4-chlorophenyl)-3-((6-nitro-2-phenylquinolin-4-yl)methoxy)-4H-chromen-4-one (4c). Yield: 91% as yellow semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.35 (d, J = 11 Hz, 2H), 8.15 (dd, J = 1.5, 10 Hz, 2H), 8.09-8.05 (m, 4H), 7.99 (d, J = 10 Hz, 1H), 7.78 (dd, J = 1.5, 10.5 Hz, 1H), 7.69-7.64 (m, 2H), 7.50-7.39 (m, 3H), 7.23-7.22 (m, 2H), 4.98 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 175.1, 160.5, 155.8, 155.5, 151.2, 146.2, 141.3, 140.2, 138.6, 136.8, 133.2, 133.6, 130.5, 130.2, 129.4, 129.0, 128.5, 125.6, 125.5, 125.1, 124.4, 123.9, 121.2, 118.3, 115.2, 86.3, 76.5. FTIR (KBr, ν = cm^{-1}): 3095, 3077, 2953, 2915, 1702, 1685, 1628, 1598, 1517, 1490, 1455, 1410, 1360, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{31}\text{H}_{19}\text{ClN}_2\text{NaO}_5$ [$\text{M}+\text{Na}$] $^+$: 557.0874, found: 557.0871.

4.3.4. 3-((6-chloro-2-phenylquinolin-4-yl)methoxy)-2-(4-chlorophenyl)-4H-chromen-4-one (4d). Yield: 89% as brownish semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.25 (dd, J = 2, 10 Hz, 1H), 8.11 (d, J = 10.5 Hz, 2H), 7.87 (d, J = 9 Hz, 2H), 7.70-7.41 (m, 6H), 7.28 (d, J = 3 Hz, 2H), 7.10 (dd, J = 3.5, 11 Hz, 2H), 6.95 (d, J = 11 Hz, 2H), 4.96 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 175.5, 161.4, 156.4, 155.3, 150.6, 138.7, 137.3, 136.2, 134.7, 134.1, 130.4, 130.2, 129.9, 129.2, 129.1, 128.8, 128.5, 128.4, 125.9, 125.4, 125.3, 123.7, 120.7, 118.1, 117.3, 86.5, 76.6. FTIR (KBr, ν = cm^{-1}): 3092, 3075, 2953, 2917, 1701, 1695, 1629, 1592, 1513, 1465, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{31}\text{H}_{19}\text{Cl}_2\text{NNaO}_3$ [$\text{M}+\text{Na}$] $^+$: 546.0634, found: 546.0635.

4.3.5. 2-(4-chlorophenyl)-3-((2-phenylbenzo[g]quinolin-4-yl)methoxy)-4H-chromen-4-one (4e). Yield: 86% as brownish semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.1-7.0 (m, 20 H), 4.83 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 175.7, 159.4, 156.5, 155.3, 153.9, 138.7, 137.3, 136.1, 134.8, 134.2, 133.7, 130.4, 130.2, 130.0, 129.7, 129.3, 129.1, 128.8, 128.5, 127.8, 126.5, 126.4, 125.8, 125.4, 123.4, 118.1, 109.5, 86.1, 76.8. FTIR (KBr, ν = cm^{-1}): 3098, 3055, 2955, 2919, 1701, 1686, 1627, 1594, 1517, 1462, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{35}\text{H}_{22}\text{ClNNaO}_3$ [$\text{M}+\text{Na}$] $^+$: 562.1180, found: 562.1169.

4.3.6. 2-(4-chlorophenyl)-3-((2-(4-(dimethylamino)phenyl)quinolin-4-yl)methoxy)-4H-chromen-4-one (4f).

Yield: 84% as pale yellow semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.14 (dd, $J = 2, 10$ Hz, 1H), 8.04 (d, $J = 11$ Hz, 1H), 7.91 (dd, $J = 1.5, 10$ Hz, 1H), 7.72 (dd, $J = 2, 10.5$ Hz, 1H), 7.64-7.62 (m, 6H), 7.46 (d, $J = 10$ Hz, 1H), 7.39 (d, $J = 11$ Hz, 1H), 7.34-7.30 (m, 1H), 7.18-7.14 (m, 2H), 6.59 (d, $J = 10$ Hz, 2H), 4.94 (s, 2H), 2.96 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 174.6, 160.3, 155.2, 155.0, 154.2, 152.7, 143.2, 141.7, 138.5, 136.7, 133.7, 133.4, 131.8, 130.1, 129.2, 129.0, 128.5, 125.5, 125.2, 124.8, 123.7, 118.0, 111.1, 110.8, 110.5, 86.0, 76.5, 39.9. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3092, 3075, 2953, 2917, 1703, 1695, 1630, 1592, 1513, 1465, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{33}\text{H}_{25}\text{ClN}_2\text{NaO}_3$ [M+Na] $^+$: 555.1445, found: 555.1441.

4.3.7. 2-(4-chlorophenyl)-3-((2-(4-nitrophenyl)quinolin-4-yl)methoxy)-4H-chromen-4-one (4g). Yield: 90% as yellow semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.34 (d, $J = 11$ Hz, 2H), 8.17 (dd, $J = 1.5, 10$ Hz, 2H), 8.08-8.03 (m, 4H), 7.98 (d, $J = 10$ Hz, 1H), 7.79 (dd, $J = 1.5, 10.5$ Hz, 1H), 7.67-7.65 (m, 2H), 7.52-7.35 (m, 3H), 7.25-7.21 (m, 2H), 4.96 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 174.8, 160.9, 155.5, 155.2, 151.1, 146.5, 141.9, 140.0, 138.6, 136.9, 133.9, 133.5, 130.5, 130.3, 129.3, 129.1, 128.7, 125.7, 125.4, 125.0, 124.3, 123.9, 121.1, 118.1, 115.3, 86.2, 76.5. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3095, 3077, 2953, 2915, 1700, 1685, 1627, 1598, 1517, 1490, 1455, 1410, 1360, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{31}\text{H}_{19}\text{ClN}_2\text{NaO}_5$ [M+Na] $^+$: 557.0874, found: 557.0865.

4.3.8. 2-(4-chlorophenyl)-3-((2-(4-chlorophenyl)quinolin-4-yl)methoxy)-4H-chromen-4-one (4h). Yield: 88% as brownish semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.16 (d, $J = 10$ Hz, 1H), 8.05 (d, $J = 11$ Hz, 1H), 7.94 (d, $J = 9.5$ Hz, 1H), 7.77-7.72 (m, 5H), 7.65-7.61 (m, 1H), 7.43-7.40 (m, 6H), 7.34 (t, $J = 9.5$ Hz, 1H), 7.21-7.17 (m, 1H), 4.96 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 174.7, 161.4, 155.4, 155.1, 152.8, 144.8, 141.8, 140.8, 138.6, 136.8, 134.6, 133.8, 133.4, 130.8, 130.2, 129.4, 129.3, 129.0, 128.6, 125.6, 125.3, 124.9, 123.8, 121.1, 118.0, 86.2, 76.5. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3092, 3075, 2953, 2917, 1699, 1695, 1627, 1592, 1513, 1465, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{31}\text{H}_{19}\text{Cl}_2\text{NNaO}_3$ [M+Na] $^+$: 546.0634, found: 546.0634.

4.3.9. 2-(4-chlorophenyl)-3-((2-(4-methoxyphenyl)quinolin-4-yl)methoxy)-4H-chromen-4-one (4i). Yield: 86% as brownish semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.22 (dd, $J = 1.5, 11.5$ Hz, 1H), 8.09 (dd, $J = 2.5, 8.5$ Hz, 2H), 8.00 (dd, $J = 1.5, 9.5$ Hz, 1H), 7.82-7.79 (m, 5H), 7.71-7.67 (m, 1H), 7.52 (d, $J = 10.5$ Hz, 1H), 7.47-7.44 (m, 3H), 7.41-7.39 (m, 1H), 7.27-7.23 (m, 1H), 6.98 (s, 1H), 4.98 (s, 1H), 3.85 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 174.9, 164.7, 155.6, 155.3, 153.0, 151.0, 145.9, 142.0, 138.7, 137.0, 133.9, 133.5, 132.1, 130.4, 130.0, 129.5, 129.1, 128.8, 125.9, 125.5, 125.1, 124.0, 120.4, 118.1, 114.4, 86.3, 76.5, 55.7. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3089, 3067, 2950, 2916, 1702, 1695, 1629, 1592, 1513, 1425, 1410, 1246, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{32}\text{H}_{22}\text{ClNNaO}_4$ [M+Na] $^+$: 542.1129, found: 542.1118.

4.3.10. 2-(4-chlorophenyl)-3-((2-(p-tolyl)quinolin-4-yl)methoxy)-4H-chromen-4-one (4j). Yield: 90% as brownish semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.23 (dd, $J = 1.5, 10$ Hz, 2H), 8.09 (d, $J = 11$ Hz, 1H), 8.00 (dd, $J = 1.5, 10$ Hz, 1H), 7.81 (dd, $J = 1.5$ Hz, 10 Hz, 2H), 7.74 (d, $J = 10.5$ Hz, 1H), 7.48-7.44 (m, 3H), 7.39 (t, $J = 1.5$ Hz, 1H), 7.29 (d, $J = 10$ Hz, 2H), 7.25-7.22 (m, 2H), 4.99 (s, 2H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 174.8, 158.5, 155.5, 155.2, 153.0, 148.1, 145.6, 143.4, 141.9, 138.7, 136.9, 134.2, 133.8, 133.5, 130.3, 129.9, 129.8, 129.4, 129.1, 128.7, 125.8, 125.4, 125.0, 123.9, 118.1, 86.3, 76.5, 21.9. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3092, 3075, 2953, 2917, 1705, 1695, 1630, 1592, 1513, 1465, 1410, 1247, 1174, 1029. HRMS

(ESI+): m/z calcd. for $\text{C}_{32}\text{H}_{22}\text{ClNNaO}_3$ [M+Na] $^+$: 526.1180, found: 526.1183.

4.3.11. 3-(((6-chloro-2-(p-tolyl)quinolin-4-yl)methoxy)-2-(4-chlorophenyl)-4H-chromen-4-one (4k). Yield: 89% as brownish semi-solid; ^1H NMR (500 MHz, CDCl_3 , ppm): δ 8.17 (m, 3H), 7.75 (d, $J = 7.5$ Hz, 2H), 7.69 (t, $J = 7$ Hz, 1H), 7.54-7.46 (m, 3H), 7.40 (t, $J = 7.5$ Hz, 1H), 7.31-7.28 (m, 2H), 7.09 (d, $J = 8$ Hz, 2H), 6.95 (d, $J = 8.5$ Hz, 2H), 4.98 (s, 2H), 2.42 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 175.2, 156.0, 155.4, 150.8, 149.0, 145.9, 141.5, 138.8, 137.2, 134.2, 134.0, 130.4, 130.0, 129.8, 129.4, 129.0, 128.8, 128.3, 125.9, 125.3, 125.2, 123.9, 120.8, 118.2, 117.4, 86.4, 76.6, 22.0. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3096, 3075, 2959, 2915, 1698, 1695, 1630, 1592, 1513, 1465, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{32}\text{H}_{21}\text{Cl}_2\text{NNaO}_3$ [M+Na] $^+$: 560.0790, found: 560.0785.

4.3.12. 3-(((6-chloro-2-(4-methoxyphenyl)quinolin-4-yl)methoxy)-2-(4-chlorophenyl)-4H-chromen-4-one (4l). Yield: 85% as pale yellow semi-solid; ^1H NMR (500 MHz, CDCl_3 , ppm): δ 8.22-8.08 (m, 2H), 7.81-7.66 (m, 4H), 7.53-7.37 (m, 3H), 7.25 (s, 1H), 7.07 (d, $J = 8$ Hz, 1H), 6.97-6.93 (m, 5H), 4.96 (s, 2H), 3.85 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 175.1, 164.8, 155.9, 155.3, 150.8, 145.7, 141.7, 138.7, 137.1, 135.6, 134.0, 132.2, 130.3, 129.8, 129.3, 129.0, 128.8, 128.2, 125.8, 125.2, 123.8, 120.8, 118.1, 117.4, 114.4, 87.0, 76.6, 55.6. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3092, 3075, 2953, 2917, 1701, 1695, 1628, 1592, 1513, 1465, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{32}\text{H}_{21}\text{Cl}_2\text{NNaO}_4$ [M+Na] $^+$: 576.0739, found: 576.0735.

4.3.13. 2-(4-chlorophenyl)-3-((2-(4-chlorophenyl)-6-(dimethylamino)quinolin-4-yl)methoxy)-4H-chromen-4-one (4m). Yield: 90% as brownish semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.21-8.09 (m, 2H), 7.69-7.67 (m, 4H), 7.52-7.37 (m, 3H), 7.05-6.94 (m, 3H), 6.62 (d, $J = 10$ Hz, 4H), 4.96 (s, 2H), 3.01 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 175.1, 155.9, 155.1, 154.5, 151.2, 145.2, 141.5, 138.6, 137.0, 134.0, 132.3, 130.3, 129.2, 129.0, 128.7, 128.0, 125.6, 125.1, 124.7, 124.5, 123.7, 121.0, 118.1, 117.4, 111.0, 86.3, 76.6, 39.9. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3092, 3075, 2953, 2917, 1701, 1695, 1629, 1592, 1513, 1465, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{33}\text{H}_{24}\text{Cl}_2\text{N}_2\text{NaO}_3$ [M+Na] $^+$: 589.1056, found: 589.1051.

4.3.14. 3-(((6-dimethylamino-2-(ferrocenyl)quinolin-4-yl)methoxy)-2-(4-chlorophenyl)-4H-chromen-4-one (4n). Yield: 85% as blackish semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.23 (dd, $J = 1.5, 10$ Hz, 1H), 8.10 (dd, $J = 2.5, 9$ Hz, 2H), 7.69-7.67 (m, 1H), 7.53 (d, $J = 10.5$ Hz, 1H), 7.48-7.45 (m, 2H), 7.42-7.38 (m, 1H), 7.28 (d, $J = 3$ Hz, 1H), 7.09 (dd, $J = 3, 11$ Hz, 2H), 6.96 (s, 1H), 4.96 (s, 2H), 4.79 (t, $J = 2.5$ Hz, 2H), 4.62 (t, $J = 2.5$ Hz, 2H), 4.25 (s, 5H), 3.01 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 175.4, 156.2, 155.3, 150.8, 146.1, 142.3, 138.7, 137.2, 134.1, 130.4, 129.3, 128.9, 128.8, 128.3, 125.8, 125.3, 125.2, 123.8, 120.8, 118.1, 117.4, 87.2, 78.4, 76.9, 73.8, 70.0, 69.9, 42.5. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3102, 3092, 3078, 2956, 2915, 1703, 1695, 1630, 1592, 1513, 1465, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{37}\text{H}_{29}\text{ClFeN}_2\text{NaO}_3$ [M+Na] $^+$: 663.1108, found: 663.1102.

4.3.15. 2-(4-chlorophenyl)-3-(((6-(dimethylamino)-2-(3,4,5-trimethoxyphenyl)quinolin-4-yl)methoxy)-4H-chromen-4-one (4o). Yield: 86% as brownish semi-solid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.09 (dd, $J = 3, 10$ Hz, 2H), 7.68-7.65 (m, 4H), 7.51-7.37 (m, 3H), 7.32-7.28 (m, 3H), 7.25 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 175.3, 156.2, 155.1, 151.0, 150.4, 147.1, 142.6, 140.0, 138.7, 137.3, 134.2, 132.4, 130.6, 130.4, 129.3, 128.8, 128.1, 125.7, 125.3, 125.1, 124.5, 123.5, 120.8, 118.1, 102.2, 86.5, 76.6, 61.0, 56.3, 42.2. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3092, 3075, 2953, 2917, 1699, 1695, 1627, 1592, 1513, 1465, 1410, 1346, 1247, 1174, 1030. HRMS (ESI+): m/z calcd. for $\text{C}_{36}\text{H}_{31}\text{ClN}_2\text{NaO}_6$ [M+Na] $^+$: 645.1762, found: 645.1756.

4.3.16. 3-((6-chloro-2-(4-nitrophenyl)quinolin-4-yl)methoxy)-2-(4-chlorophenyl)-4H-chromen-4-one (4p). Yield: 92% as yellow liquid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.33 (dd, $J = 2$, 10.5 Hz, 2H), 8.21 (d, $J = 10.5$ Hz, 1H), 8.09-8.01 (m, 2H), 8.03-8.01 (m, 2H), 7.70-7.66 (m, 1H), 7.53 (d, $J = 10.5$ Hz, 1H), 7.45 (dd, $J = 3$, 11 Hz, 2H), 7.41-7.37 (m, 1H), 7.25-7.24 (m, 2H), 7.09-7.07 (m, 1H), 6.93 (d, $J = 3\text{H}$), 4.93 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 175.5, 156.4, 155.4, 151.2, 150.6, 147.0, 142.6, 140.0, 138.7, 137.3, 134.2, 132.4, 130.6, 130.4, 129.3, 128.8, 128.4, 125.9, 125.4, 125.3, 124.4, 123.7, 120.7, 118.2, 117.4, 87.6, 76.7. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3092, 3075, 2953, 2917, 1695, 1693, 1624, 1592, 1513, 1455, 1418, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{31}\text{H}_{18}\text{Cl}_2\text{N}_2\text{NaO}_5$ [$\text{M}+\text{Na}$] $^+$: 591.0484, found: 591.0475.

4.3.17. 2-(4-chlorophenyl)-3-((6-(dimethylamino)-2-(furan-2-yl)quinolin-4-yl)methoxy)-4H-chromen-4-one (4q). Yield: 87% as black-brown liquid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.21 (d, $J = 10$ Hz, 1H), 8.09 (d, $J = 10.5$ Hz, 1H), 7.69-7.67 (m, 2H), 7.53 (d, $J = 10.5$ Hz, 1H), 7.45 (d, $J = 10$ Hz, 1H), 7.41-7.37 (m, 1H), 7.26-7.25 (m, 3H), 7.08-7.05 (m, 2H), 6.93 (dd, $J = 1$, 11 Hz, 2H), 6.58 (s, 1H), 4.94 (s, 2H), 3.01 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 175.3, 160.9, 156.2, 155.3, 152.9, 150.8, 148.5, 143.2, 138.7, 137.2, 134.1, 132.1, 130.4, 129.2, 128.9, 128.8, 128.2, 125.8, 125.3, 125.2, 123.7, 121.8, 120.8, 118.1, 117.4, 112.8, 76.7, 41.8. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3092, 3075, 2953, 2917, 1701, 1695, 1628, 1592, 1513, 1465, 1410, 1348, 1321, 1247, 1174, 1042. HRMS (ESI+): m/z calcd. for $\text{C}_{31}\text{H}_{23}\text{ClN}_2\text{NaO}_4$ [$\text{M}+\text{Na}$] $^+$: 545.1238, found: 545.1229.

4.3.18. 7-((6-chloro-2-(4-nitrophenyl)quinolin-4-yl)methoxy)-4-methyl-2H-chromen-2-one (5a). Yield: 94% as brown liquid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.38 (d, $J = 11$ Hz, 3H), 8.07 (d, $J = 10.5$ Hz, 3H), 7.52 (d, $J = 11.5$ Hz, 1H), 7.30 (d, $J = 3$ Hz, 1H), 7.12 (dd, $J = 3$, 11 Hz, 2H), 6.92 (d, $J = 4$ Hz, 1H), 6.16 (s, 1H), 4.75 (s, 2H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 163.4, 161.7, 160.5, 155.1, 153.0, 151.2, 150.5, 140.1, 136.1, 130.7, 128.8, 128.6, 125.8, 125.6, 124.4, 120.6, 117.3, 114.4, 113.0, 112.4, 102.2, 86.1, 72.4, 18.8. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3105, 3078, 2958, 2917, 1720, 1628, 1599, 1513, 1475, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{26}\text{H}_{17}\text{ClN}_2\text{NaO}_5$ [$\text{M}+\text{Na}$] $^+$: 495.0718, found: 495.0712.

4.3.19. 7-((6-chloro-2-(p-tolyl)quinolin-4-yl)methoxy)-4-methyl-2H-chromen-2-one (5b). Yield: 91% as brown liquid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.78 (d, $J = 10$ Hz, 2H), 7.53 (d, $J = 7.53$, $J = 10.5$ Hz, 1H), 7.34-7.30 (m, 4H), 7.12 (dd, $J = 10$, 18 Hz, 2H), 6.97-6.93 (m, 2H), 6.18 (s, 1H), 4.76 (s, 2H), 2.44 (s, 3H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 162.7, 161.6, 160.3, 154.7, 152.9, 150.4, 145.6, 135.8, 133.9, 129.8, 129.6, 128.6, 128.2, 125.5, 125.1, 120.5, 117.1, 114.1, 112.8, 112.0, 101.9, 86.6, 72.4, 21.7, 18.5. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3105, 3078, 2958, 2917, 1725, 1627, 1513, 1465, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{27}\text{H}_{20}\text{ClN}_2\text{NaO}_3$ [$\text{M}+\text{Na}$] $^+$: 464.1023, found: 464.1019.

4.3.20. 7-((6-chloro-2-(4-methoxyphenyl)quinolin-4-yl)methoxy)-4-methyl-2H-chromen-2-one (5c). Yield: 89% as light yellow liquid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.85 (d, $J = 11$ Hz, 2H), 7.54 (d, $J = 11.5$ Hz, 1H), 7.32 (d, $J = 3$ Hz, 1H), 7.14 (dd, $J = 3$, 10.5 Hz, 2H), 7.01 (d, $J = 11$ Hz, 2H), 6.97-6.94 (m, 3H), 6.19 (s, 1H), 4.84 (s, 2H), 3.90 (s, 3H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 164.9, 161.9, 160.6, 155.1, 153.1, 150.6, 134.4, 132.3, 129.9, 128.8, 128.5, 125.8, 125.5, 123.5, 120.7, 117.3, 114.5, 114.4, 113.1, 112.4, 102.2, 86.8, 76.7, 55.7, 18.8. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3105, 3078, 2958, 2917, 1723, 1629, 1592, 1513, 1465, 1410, 1245, 1173, 1024. HRMS (ESI+): m/z calcd. for $\text{C}_{27}\text{H}_{20}\text{ClN}_2\text{NaO}_4$ [$\text{M}+\text{Na}$] $^+$: 480.0973, found: 480.0965.

4.3.21. 7-((6-chloro-2-(3,4,5-trimethoxyphenyl)quinolin-4-yl)methoxy)-4-methyl-2H-chromen-2-one (5d). Yield: 85% as brown liquid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.02 (d, $J = 10.5$ Hz,

1H), 7.79 (d, $J = 3$ Hz, 1H), 7.63 (s, 3H), 7.60 (dd, $J = 3$, 11 Hz, 1H), 7.45-7.41 (m, 3H), 6.65 (s, 1H), 5.26 (s, 2H), 3.80 (s, 9H), 2.4 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 162.5, 161.5, 160.5, 155.0, 153.7, 152.9, 150.7, 143.6, 137.9, 131.7, 128.9, 128.2, 125.7, 125.2, 120.7, 117.3, 114.3, 112.9, 112.3, 106.8, 102.2, 86.3, 76.6, 61.0, 56.3, 18.7. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3105, 3078, 2958, 2917, 1726, 1627, 1593, 1513, 1468, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{29}\text{H}_{24}\text{ClN}_2\text{NaO}_6$ [$\text{M}+\text{Na}$] $^+$: 540.1184, found: 540.1186.

4.3.22. 7-((6-chloro-2-(4-chlorophenyl)quinolin-4-yl)methoxy)-4-methyl-2H-chromen-2-one (5e). Yield: 86% as brown liquid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.33-8.32 (m, 3H), 8.01-7.99 (m, 4H), 7.62-7.59 (m, 1H), 7.46-7.43 (m, 3H), 6.66 (s, 1H), 5.26 (s, 2H), 2.42 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 162.5, 161.5, 160.5, 155.0, 152.8, 150.7, 141.1, 137.7, 134.7, 131.0, 129.5, 128.9, 128.3, 125.8, 125.3, 120.7, 117.3, 114.3, 112.9, 112.4, 102.2, 86.5, 76.6, 18.7. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3102, 3078, 2958, 2917, 1722, 1629, 1595, 1513, 1465, 1410, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{26}\text{H}_{17}\text{Cl}_2\text{N}_2\text{NaO}_3$ [$\text{M}+\text{Na}$] $^+$: 484.0477, found: 484.0469.

4.3.23. 7-((6-chloro-2-(furan-2-yl)quinolin-4-yl)methoxy)-4-methyl-2H-chromen-2-one (5f). Yield: 88% as brown liquid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.75 (t, $J = 1$ Hz, 1H), 7.58 (dd, $J = 3$, 9 Hz, 1H), 7.35 (d, $J = 3$ Hz, 2H), 7.31 (dd, $J = 0.5$, 3 Hz, 1H), 7.16 (dd, $J = 3.5$, 11 Hz, 2H), 7.01-6.97 (m, 2H), 6.66-6.65 (m, 1H), 6.21 (s, 1H), 4.85 (s, 2H), 2.44 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 162.9, 161.6, 160.5, 155.0, 153.0, 152.9, 150.7, 148.3, 136.1, 128.9, 128.4, 125.8, 125.3, 121.5, 120.7, 117.4, 114.3, 112.9, 112.8, 112.4, 102.2, 86.3, 76.6, 18.8. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3107, 3075, 2953, 2915, 1725, 1630, 1595, 1513, 1465, 1410, 1247, 1174, 1024. HRMS (ESI+): m/z calcd. for $\text{C}_{24}\text{H}_{16}\text{ClN}_2\text{NaO}_4$ [$\text{M}+\text{Na}$] $^+$: 440.0660, found: 440.0664.

4.3.24. 7-((6-chloro-2-(1H-indol-3-yl)quinolin-4-yl)methoxy)-4-methyl-2H-chromen-2-one (5g). Yield: 85% as brown liquid; ^1H NMR (500 MHz, CDCl_3 , ppm): δ 8.17 (br, s, 1H, D_2O exchangeable), 7.75 (d, $J = 8$ Hz, 1H), 7.42-7.37 (m, 3H), 7.29 (t, $J = 7$ Hz, 1H), 7.22 (t, $J = 7$ Hz, 1H), 7.18-7.16 (m, 3H), 6.99 (m, 2H), 6.63 (s, 1H), 6.20 (s, 1H), 4.74 (s, 2H), 2.35 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 162.6, 160.6, 160.2, 155.7, 154.1, 152.5, 144.8, 136.3, 132.5, 131.0, 130.7, 128.4, 125.6, 124.3, 123.2, 121.4, 121.2, 120.9, 119.6, 114.0, 112.3, 111.5, 110.8, 110.2, 102, 86.4, 76.6, 18.5. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3307, 3114, 3075, 2958, 2917, 1723, 1628, 1599, 1515, 1463, 1410, 1247, 1174, 1024. HRMS (ESI+): m/z calcd. for $\text{C}_{28}\text{H}_{19}\text{ClN}_2\text{NaO}_3$ [$\text{M}+\text{Na}$] $^+$: 489.0976, found: 489.0968.

4.3.25. 7-((6-chloro-2-(ferrocenyl)quinolin-4-yl)methoxy)-4-methyl-2H-chromen-2-one (5h). Yield: 80% as black liquid; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.50 (d, $J = 10.5$ Hz, 1H), 7.29 (s, 1H), 7.10 (d, $J = 3.5$ Hz, 2H), 6.91 (d, $J = 11$ Hz, 3H), 6.15 (s, 1H), 4.78 (s, 2H), 4.73 (s, 2H), 4.61 (s, 2H), 2.38 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 161.9, 160.5, 155.0, 153.2, 150.8, 147.6, 133.5, 128.9, 128.4, 125.8, 125.3, 120.8, 117.4, 114.3, 113.0, 112.3, 102.2, 86.5, 79.1, 76.7, 73.7, 69.9, 69.9, 18.8. FTIR (KBr, $\nu = \text{cm}^{-1}$): 3102, 3077, 2952, 2915, 1720, 1629, 1594, 1515, 1465, 1412, 1247, 1174, 1029. HRMS (ESI+): m/z calcd. for $\text{C}_{30}\text{H}_{22}\text{ClFeN}_2\text{NaO}_3$ [$\text{M}+\text{Na}$] $^+$: 558.0529, found: 558.0518.

4.4. Biological activity

4.4.1. Antibacterial assay. Minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial compound that inhibits the visible growth of a microorganism. MIC values of the compounds against bacterial isolates were determined on the basis of micro-well dilution method following National committee for clinical laboratory standards (NCCLS) recommendations.³² In this method we made stock of chemically synthesized compounds at a

concentration of 10 mg/ml in DMSO, which was further converted to working solution of concentration 1 mg/ml. Using a micropipette, 100 μ l of media into all wells of pre-sterilized micro titre plate was dispensed (experiment was done in triplicate). Two fold serial dilutions (100, 50, 25, 0.78125 mg/mL) were carried out from the well # 1 to the well # 10 and excess media (100 μ l) was discarded from the last well (# 10). Liquid broth culture of test organism was grown to log phase in Luria Bertani broth (LB broth) for 24 h at 37 °C. The optical density of liquid culture was determined at 600 nm and diluted in such a way that each well received 107 cfu/ ml of bacterial culture. Appropriate positive and negative control was also included in the study. Positive control contained only microbial cells whereas negative control contained only standard drug solution (Ampicillin and Cefadroxil). All experimental procedures were performed under sterile condition using bio-safety hood and microtitre plates were incubated at 37 °C for 24 h.

4.4.2. Antifungal assay. MIC of standard antifungal drugs viz. Fluconazole and the synthesized compounds against fungal isolates were determined by the broth micro dilution method as described by the NCCLS, 1997.³² Liquid broth culture of test organism was grown to a suitable phase in Yeast, Peptone, and D-Glucose (YPD) media for 48 h at 30 °C. The optical density of liquid culture was determined at 600 nm and diluted in such a way that each well received 104 cfu/ml of fungal suspension. The further procedure was similar to above mentioned antibacterial assay.

Acknowledgements

The authors wish to express their gratitude to the BRNS, India for financial support, DST, New Delhi for providing HRMS facility and CSIR, New Delhi for awarding SRF to S.K.

Supplementary Material

Characterization data ¹H, and ¹³C NMR spectra associated with this article are available.

Notes and references

- S.A. Jenekhe, L. Lu, M.M. Alam, *Macromolecules*, 2001, **34**, 7315.
- A.C. Grimdsdale, K.L. Chan, R.E. Martin, G.J. Pawel, A.B. Holmes, *Chem. Rev.*, 2009, **109**, 897.
- (a) R. Jain, B. Vaitilingam, A. Nayyar, P.B. Palde, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 1051; (b) M. Jain, S. Vangapanda, S. Sachdeva, S. Singh, P.P. Singh, G.B. Jena, K. Tikoo, P. Ramarao, C.L. Kaul, R. Jain, *J. Med. Chem.*, 2004, **47**, 285; (c) S. Vangapandu, M. Jain, R. Jain, S. Kaur, P.P. Singh, *Bioorg. Med. Chem.*, 2004, **12**, 2501.
- (a) A. Mai, D. Rotili, D. Tarantino, P. Ornaghi, F. Tosi, C. Vicidomini, G. Sbardella, A. Nebbioso, M. Miceli, L. Altucci, P. Filetici, *J. Med. Chem.*, 2006, **49**, 6897; (b) A. Shi, T.A. Nguyen, S.K. Battina, S. Rana, D.J. Takemoto, P.K. Chiang, D.H. Hua, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 3364.
- (a) A. Mai, D. Rotili, D. Tarantino, A. Nebbioso, S. Castellano, G. Sbardella, M. Tini, L. Altucci, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 1132; (b) K. Kaur, M. Jain, R.P. Reddy, R. Jain, *Eur. J. Med. Chem.*, 2010, **45**, 3245; (c) V.R. Solomon, H. Lee, *Curr. Med. Chem.*, 2011, **18**, 1488.
- (a) Y. Ding, T.D.T. Nguyen, D.H. Hua, T.A. Nguyen, *Anticancer Drugs*, 2012, **23**, 897; (b) T. Yamaguchi, S. Watanabe, Y. Matsumura, Y. Tokuyama, A. Yokoyama, *Bioorg. Med. Chem.*, 2012, **20**, 3058.
- (a) V. Monga, A. Nayyar, B. Vaitilingam, P. B. Palde, S. S. Jhamb, S. Kaur, P.P. Singh, R. Jain, *Bioorg. Med. Chem.*, 2004, **12**, 6465; (b) Y. Ding, T.A. Nguyen, *Apoptosis*, 2013, **18**, 1071.
- M.R. Heinrich, W. Steglich, M.G. Banwell, Y. Kashman, *Tetrahedron*, 2003, **59**, 9239.
- O. Doebner, W. von Miller, *Ber. Dtsch. Chem. Ges.*, 1883, **16**, 2464.
- W. Pfiztinger, *J. Prakt. Chem.*, 1886, **33**, 100.
- A.J. Hodgkinson B. Staskun, *J. Org. Chem.*, 1969, **34**, 1709.
- A. Combes, *Bull. Soc. Chim. Fr.*, 1888, **49**, 89.
- P. Friedlander, *Ber. Dtsch. Chem. Ges.*, 1882, **15**, 2572.
- X.-L. Chen, J.-M. Zhang, W.-L. Shang, B.-Q. Lu, J.-A. Jin, *J. Fluorine Chem.*, 2012, **133**, 139.
- J. Zhang, W. Yang, L. Song, X. Caib, S. Zhub, *Tetrahedron Lett.*, 2004, **45**, 5771.
- H. Huang, H. Jiang, K. Chen, H. Liu, *J. Org. Chem.*, 2009, **74**, 5476; (b) C. E. Meyet, C. H. Larsen *J. Org. Chem.*, 2014, **79**, 9835.
- D. Duvelleroy, C. Perrio, O. Parisel, M.-C. Lasne, *Org. Biomol. Chem.*, 2005, **3**, 3794.
- Y. Zhang, P. Li, L. Wang, *J. Heterocycl. Chem.*, 2011, **48**, 153.
- C. Yao, B. Qin, H. Zhang, J. Lu, D. Wang, S. Tu, *RSC Adv.*, 2012, **2**, 3759.
- X.-S. Wang, J. Zhou, M.-M. Zhang, W. Wang, Y.-L. Li, *Monatsh Chem.*, 2012, **143**, 935.
- F. Xiao, Y. Chen, Y. Liu, J. Wang, *Tetrahedron*, 2008, **64**, 2755.
- A. Andrade, G.C. Santos, L.C. Silva-Filho, *J. Heterocycl. Chem.*, 2015, **52**, 273.
- J. Tang, L. Wang, D. Mao, W. Wang, L. Zhang, S. Wu, Y. Xie, *Tetrahedron*, 2011, **67**, 8465.
- V. Gaddam, S. Ramesh, R. Nagarajan, *Tetrahedron*, 2010, **66**, 4218.
- A. Kulkarni, B. Torok, *Green Chem.*, 2010, **12**, 875.
- (a) E.L. Lu, Y.X. Li, Y.F. Chen, *Chem. Commun.*, 2010, **46**, 4469; (b) A. Nojiri, N. Kumagai, M. Shibasaki, *J. Am. Chem. Soc.*, 2008, **130**, 5630; (c) M. Takimoto, S. Usami, Z.M. Hou, *J. Am. Chem. Soc.*, 2009, **131**, 18266; (d) W. Gao, D.M. Cui, *J. Am. Chem. Soc.*, 2008, **130**, 4984; (e) J.T. Sun, M.H. Yang, F. Yuan, X.F. Jia, X. Yang, Y. Pan, C. Zhu, *J. Adv. Synth. Catal.*, 2009, **351**, 920; (f) Z.X. Zhang, L.X. Zhang, Y.R. Li, L.C. Hong, Z.X. Chen, X.G. Zhou, *Inorg. Chem.*, 2010, **49**, 5715.
- (a) S. Kobayashi, M. Sugiura, H. Kitagawa, W.W.-L. Lam, *Chem. Rev.*, 2002, **102**, 2227; (b) W. Rao, X. Zhang, P.W.H. Chan, E.M.L. Sze, *J. Org. Chem.*, 2009, **74**, 1740; (c) T.P. Lebold, M.A. Kerr, *Org. Lett.*, 2009, **11**, 4354; (d) J.G. Ruano, M.C. Maestro, *J. Org. Chem.*, 2009, **74**, 1200; (e) B. Hu, J. Zhu, S. Xing, J. Fang, D. Du, Z. Wang, *Chem.-Eur. J.*, 2009, **15**, 324; (f) K. Aplander, R. Ding, U.M. Lindstrom, J. Wennerberg, S. Schultz, *Angew. Chem. Int. Ed.*, 2007, **46**, 4543.
- (a) S. Kobayashi, *Synlett*, 1994, 689; (b) S. Kobayashi, *Chem. Lett.*, 1991, 2187.
- M. Kumar, T. Kaur, V. K. Gupta, A. Sharma, *RSC Adv.* 2015, **5**, 17087.
- D.M. D'Souza, T.J. Müller, *J. Chem. Soc. Rev.*, 2007, **36**, 1095.
- (a) S. Kumar, N. Verma, I. Parveen, N. Ahmed, *J. Hetrocycl. Chem.*, 2015, DOI: 10.1002/jhet.2517; (b) N. Ahmed, N. K. Konduru, S. Ahmad, M. Owais, *Eur. J. Med. Chem.*, 2014, **82**, 552; (c) N. Verma, V. Kundi, N. Ahmed, *Tetrahedron Lett.*, 2015, **56**, 4175; (d) J.M. Beauregard, E. Croteau, N. Ahmed, R. Ouellet, J. E. van Lier, F. Benard, *Nuc. Med. and Biol.*, 2007, **34**, 325; (e) N. Ahmed, N.K. Konduru, S. Ahmed, M. Owais, *Eur. J. Med. Chem.*, 2014, **75**, 233; (f) J.M. Beauregard, E. Croteau, N. Ahmed, J.E. van Lier, F.T. Benard,

J. Nuc. Med., 2009, **50**, 100; (g) N. Ahmed, J. E. Van Lier, *Tetrahedron Lett.*, 2007, **48**, 5407; (h) N. Ahmed, J. E. Van Lier, *Tetrahedron Lett.*, 2006, **47**, 2725; (i) N. Ahmed, N. K. Konduru, *Beilstein J. Org. Chem.*, 2012, **8**, 177; (j) S. Kumar, N. Ahmed, *Green Chem.*, 2015, DOI: 10.1039/c5gc01785h; (k) S. Kumar, N. Ahmed, *RSC Adv.*, 2015, **5**, 77075; (l) S. Kumar, N. Konduru, N. Verma, N. Ahmed, *Synth. Commun.*, 2015, DOI: 10.1080/00397911.2015.1093142; (m) S. Kumar, N. Verma, N. Ahmed, *RSC Adv.*, 2015, doi: 10.1039/c5ra15996b.

32 J.R. Zgoda, J.R. Porter, *Pharm. Biol.*, 2001, **39**, 221.

